Skip to main content
Elsevier
View Cart

Prostate Cancer Metabolism

From Biochemistry to Therapeutics

  • 1st Edition - June 25, 2021
  • Latest edition
  • Authors: Tomas Koltai, Stephan J. Reshkin, Fatima Baltazar, Larry Fliegel
  • Language: English

Prostate Cancer Metabolism: From Biochemistry to Therapeutics shows the peculiarities of prostate cancer metabolism, emphasizing the targetable aspects – that have not been cons… Read more

World Book Day celebration

Where learning shapes lives

Up to 25% off trusted resources that support research, study, and discovery.

Explore resources

Description

Prostate Cancer Metabolism: From Biochemistry to Therapeutics shows the peculiarities of prostate cancer metabolism, emphasizing the targetable aspects – that have not been considered in conventional treatment protocols. The book specifically addresses treatment of the castration-resistant stage of prostate cancer proposing many repurposed drugs and nutraceuticals to complement, not replace, standard therapies. The large body of evidence supporting these concepts makes them deserving of further research and well-designed clinical trials. It discusses lipid, cholesterol, glutamine, and glucose metabolisms and their impact on prostate cancer. Additionally, it explains how current established drugs can be repurposed to improve treatment outcomes.

The concepts set out in the book, that deal with cancer at the cellular/molecular level, help identify new avenues of research and treatments to pursue that do not affect well-being whilst offer consistent benefits. Since most practicing physicians have not studied basic biochemistry since medical school, each chapter begins with a brief review of the topic to facilitate an understanding of the metabolically-oriented approach to targeting prostate cancer. Conventional treatments are not discussed here since they are covered in textbooks and specialized updates that abound in the medical literature.

It is a valuable resource for cancer researchers, oncologists, clinicians and members of biomedical field who want to learn more about prostate cancer metabolism and how to apply recent findings in the field to bedside.

Key features

  • Explains the basic aspects of prostate cancer metabolism, including its biochemistry which has a pivotal role in clinical practice
  • Discusses new drugs and nutraceuticals with a metabolism-centered approach
  • Offers practical bedside approach in combination with molecular and biochemical fundamentals to help readers identify and provide the best treatment to their patients

Readership

Oncologists, cancer researchers, clinicians. Urologists

Table of contents

1. Introductory words: cell metabolism and systems biology2. Introduction to prostate cancer metabolism and treatment with nonconventional drugs3A. The conductors of the metabolic orchestra: part I3B. Phosphatase and tensin homolog deleted in chromosome 10: another metabolic regulator in prostate cancer?4. Lipid metabolism part I: an overview5. Lipid metabolism part II: sphingolipids and ceramides6. Fatty acid synthesis and prostate cancer7. Cholesterol metabolism in prostate cancer8. Glutamine metabolism in prostate cancer9. Carbohydrate metabolism in prostate cancer10. pH and electrolytes metabolism in prostate cancer11. Iron metabolism in prostate cancer12. Androgen metabolism in castration-resistant prostate cancer13. Summary, discussion, and conclusions

Product details

  • Edition: 1
  • Latest edition
  • Published: June 25, 2021
  • Language: English

About the authors

TK

Tomas Koltai

Tomas Koltai is Board Certified Specialist in Medical Oncology (1985), PhD in Chemistry (1997) and Master’s in Sciences in Molecular Oncology, University of Buenos Aires (2011). He has vast experience on cancer treatment at several positions: staff oncologist, Sanatorio Mater Dei, Argentina (1985-1990); Head of Oncology, Central Hospital of the Centro Gallego de Buenos Aires (1990-2000) and Medical Director, at the same institution (2000-2002); Head of the Department of Chemotherapy, National Social Services for Retirees, Argentina (2002-2014); Head of the Department of Oncology, Social Services of the National Food Workers Union, Argentina (2010-2014) and Medical Director at the same institution (2014-2016). He has authored several seminal publications on cancer and created the new “triple-edged cancer treatment”.
Affiliations and expertise
Former Medical Director, Hospital del Centro Gallego de Buenos Aires, Argentina

SR

Stephan J. Reshkin

Stephan Reshkin, PhD, is molecular biologist and Associate Professor at the University of Bari (Italy). Dr. Reshkin has published 108 scientific papers, several book chapters and co-authored An Innovative Approach to Understanding and Treating Cancer: Targeting pH (Elsevier, 2020). His main research interests are cancer cell and pancreatic ductal adenocarcinoma.
Affiliations and expertise
Associate Professor, Department of Biosciences, Biotechnology and Biopharmaceutics, University of Bari, Italy

FB

Fatima Baltazar

Fátima Baltazar holds a degree in Pharmaceutical Sciences by the University of Coimbra (Portugal, 1991), a PhD by the University of Hull (UK, 1998) and has postdoctoral experience at the University of Minho (Portugal, 1998-2003). She is currently Associate Professor at the Medical School of University of Minho (Portugal). Fatima joined ICVS (Life and Health Sciences Research Institute) team in 2004 and she is currently Principal Investigator and Coordinator of the Surgical Sciences Research Domain (SSRD). She started her research on the Cancer field in 2005 and, in the last years, Fatima’s main research interest has been on cancer metabolism, focusing on the discovery of new prognostic metabolic biomarkers and cancer therapeutic targets, using human samples and suitable in vitro and in vivo cancer models. Fátima has published 104 international peer-reviewed research articles, 8 book chapters and she is also (co-)inventor on two national patent applications.
Affiliations and expertise
Associate Professor, Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal

LF

Larry Fliegel

Research in Dr. Fliegel’s laboratory investigates membrane proteins’ function, how intracellular pH is regulated and the role of Na+/H+ exchanger in human disease, especially heart disease and breast cancer. The work was funded by CIHR and other sources. Dr. Fliegel has published over 150 publications in numerous journals including J. Biological Chemistry, J. Molecular and Cellular Cardiology, Hypertension, Cancer Research, Basic Research in Cardiology and others. He has authored two books and served on several editorial boards of Journals and grant panels such as CIHR. His awards include a Killam Annual Professor Award (2009-10), a Tier one Basic Science Mentoring Award (2013), McCalla Research Professorship Award (2007) and Alberta Heritage Foundation for Medical Research Scientist Award (2006-2013).
Affiliations and expertise
Professor Emeritus, Department of Biochemistry, Faculty of Medicine, University of Alberta, Canada

View book on ScienceDirect

Read Prostate Cancer Metabolism on ScienceDirect